Novartis is a global healthcare company based in Basel, Switzerland. The company’s portfolio includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices.
The company operates in three reporting segments including Innovative Medicines (formerly named the Pharmaceuticals Division), Sandoz and Alcon. About 123,000 people of 144 nationalities work at Novartis globally. The company recorded sales of USD 49.4 billion, a decrease by 5% compared to USD 52.2 billion in 2014 due to the amortization of new oncology assets in the Pharmaceuticals Division and negative currency impacts. The earnings per share in 2015 was USD 7.40. The total pharmaceuticals sales in 2015 was USD 30.4 billion accounting for 61.6% of the total sales. The pharmaceutical sales of the company in 2015 declined by 4% (compared to 2014) owing to acquisition of oncology portfolio from GlaxoSmithKline (GSK) in and increased impact of generic competition.
In 2016, Novartis stood at USD 36.2 billion, a decrease of 2%, as compared to 2015 fiscal nine months sales. The fiscal third quarter (Q3) sales were USD 12.1 billion, a decrease of 1% compared to 2015 Q3 sales with earnings per share at USD 0.8. The company recorded a total pharmaceutical sales of fiscal nine months at USD 24.3 billion in 2016 which is 2% lower as compared to the same period in 2015, offset by the impact of generic competition and negative currency impacts. Q3 2016 pharmaceutical sales stood at USD 8.2 billion a decrease of 1% as compared to Q3 2015 due to Gleevec/Glivec genericization in the US along with increased operating income.
Strategic highlights: (Q3, 2016)
NGENUITY 3D Visualization System, a platform for Digitally Assisted Vitreoretinal Surgery (DAVS). (Sep)
Office point of care diagnostic tool – the Niji System and Total IgE Test to provide ease of diagnosis of severe allergic asthma and faster treatment decisions. (Sep)
Dailies Total1 Multifocal water gradient contact lenses for people with presbyopia. (July)
The Kenya Red Cross Society (KRCS) to improve access to prevention, treatment, and care of Non Communicable Diseases (NCDs) in Kenya. (Aug)
U.S. FDA approval for the CyPass Micro-Stent, a micro invasive glaucoma surgical (MIGS) device. (Aug)
Granted U.S. FDA Breakthrough Therapy designation to LEE011 (ribociclib) to treat metastatic breast cancer. (Aug)
U.S. FDA approved Sandoz Erelzi(TM) to treat multiple inflammatory diseases. (Aug)
Biosimilar etanercept approved by U.S. FDA advisory to treat multiple inflammatory diseases. (July)
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.
Sources: Annual report, quarterly report, investor’s presentation, company website, and press releases